Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK plus non-small-cell lung cancer (NSCLC)

F. Barlesi, A-M. C. Dingemans, J. C-H. Yang, S-H. I. Ou, J. S. Ahn, L. De Petris, B. Hughes, H. Lena, W. Bordogna, S. Golding, P. N. Morcos, B. Balas, A. Zeaiter, D-W. Kim

Research output: Contribution to journalConference Abstract/Poster in journalAcademic

Original languageEnglish
Article number1263P
Number of pages1
JournalAnnals of Oncology
Issue numbersupp. 6
Publication statusPublished - 1 Oct 2016

Cite this